Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Phase 2

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: Pembrolizumab
Biological: Boserolimab
Biological: MK-4830
Biological: MK-0482
Drug: diphenhydramine
Drug: acetaminophen

First Posted Date: 2019-11-15

Last Posted Date: 2024-12-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 135

Registration Number: NCT04165096

Locations: 🇺🇸
Cleveland Clinic Main ( Site 0006), Cleveland, Ohio, United States
🇺🇸
Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States
🇺🇸
City of Hope ( Site 0014), Duarte, California, United States

and more 36 locations

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Phase 2

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: Pembrolizumab
Drug: Carboplatin
Biological: MK-0482
Drug: Pemetrexed
Biological: HER3-DXd
Biological: Ifinatamab Deruxtecan (I-DXd)
Drug: Paclitaxel
Biological: Vibostolimab
Biological: MK-4830
Biological: Boserolimab

First Posted Date: 2019-11-15

Last Posted Date: 2025-05-01

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 450

Registration Number: NCT04165070

Locations: 🇺🇸
Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States
🇺🇸
City of Hope ( Site 0014), Duarte, California, United States
🇺🇸
UCSF Medical Center at Mission Bay ( Site 0007), San Francisco, California, United States

and more 36 locations

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Phase 2

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: Pembrolizumab
Biological: MK-4830
Biological: MK-0482

First Posted Date: 2019-11-15

Last Posted Date: 2024-11-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 120

Registration Number: NCT04165083

Locations: 🇺🇸
MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland, United States
🇺🇸
Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital ( Site 0003), Boston, Massachusetts, United States

and more 36 locations

A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)

Phase 1

Completed

Conditions: Mesothelioma

Interventions: Drug: Pembrolizumab
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2019-11-06

Last Posted Date: 2024-03-22

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 19

Registration Number: NCT04153565

Locations: 🇯🇵
Kanagawa Cancer Center ( Site 0004), Yokohama, Kanagawa, Japan
🇯🇵
JOHAS Okayama Rosai Hospital ( Site 0002), Okayama, Japan
🇯🇵
Hyogo College of Medicine Hospital ( Site 0003), Nishinomiya, Hyogo, Japan

and more 1 locations

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Phase 2

Terminated

Conditions: Advanced/Metastatic Melanoma

Interventions: Biological: Gebasaxturev IV
Biological: Gebasaxturev ITu
Drug: Pembrolizumab

First Posted Date: 2019-11-05

Last Posted Date: 2024-08-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 85

Registration Number: NCT04152863

Locations: 🇩🇪
Universitaetsklinikum Regensburg ( Site 2007), Regensburg, Bayern, Germany
🇺🇸
Rutgers Cancer Institute of New Jersey ( Site 0002), New Brunswick, New Jersey, United States
🇺🇸
Providence Portland Medical Center [Portland, OR] ( Site 0005), Portland, Oregon, United States

and more 27 locations

A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

Phase 1

Terminated

Conditions: Neoplasm Metastasis

Interventions: Drug: 200 mg of pembrolizumab
Biological: V938

First Posted Date: 2019-10-22

Last Posted Date: 2024-11-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 35

Registration Number: NCT04135352

Locations: 🇮🇱
Rambam Health Care Campus-Oncology Division ( Site 0020), Haifa, Israel
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0002), San Francisco, California, United States
🇺🇸
MD Anderson Cancer Center ( Site 0001), Houston, Texas, United States

and more 3 locations

MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)

Phase 3

Completed

Conditions: Cytomegalovirus Infection
Cytomegalovirus Disease

Interventions: Drug: Letermovir tablet
Drug: Letermovir IV

First Posted Date: 2019-10-16

Last Posted Date: 2024-08-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 22

Registration Number: NCT04129398

Locations: 🇯🇵
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital ( Site 0002), Nagoya, Aichi, Japan
🇯🇵
Sapporo City General Hospital ( Site 0004), Sapporo, Hokkaido, Japan
🇯🇵
Osaka University Hospital ( Site 0003), Suita, Osaka, Japan

and more 1 locations

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Phase 2

Active, not recruiting

Conditions: Solid Tumors

Interventions: Drug: Olaparib
Biological: Pembrolizumab

First Posted Date: 2019-10-10

Last Posted Date: 2025-03-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 300

Registration Number: NCT04123366

Locations: 🇦🇺
Monash Medical Centre ( Site 2205), Clayton, Victoria, Australia
🇦🇷
CEMIC ( Site 2701), Buenos Aires, Argentina
🇩🇪
Universitaetsklinik Koeln ( Site 0903), Koeln, Nordrhein-Westfalen, Germany

and more 132 locations

Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)

Phase 2

Completed

Conditions: Respiratory Syncytial Viruses

Interventions: Biological: Clesrovimab
Other: Placebo
Biological: RSV-A Memphis 37b

First Posted Date: 2019-09-11

Last Posted Date: 2022-09-14

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 80

Registration Number: NCT04086472

Locations: 🇬🇧
HVIVO Services Ltd ( Site 0001), London, United Kingdom

Gluten Challenge Study in Celiac Disease Participants (MK-0000-402)

Early Phase 1

Completed

Conditions: Celiac Disease

Interventions: Dietary Supplement: Gluten powder 4g

First Posted Date: 2019-08-13

Last Posted Date: 2023-03-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 18

Registration Number: NCT04054544

Locations: 🇺🇸
Massachusetts General Hospital ( Site 0001), Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center ( Site 0002), Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy